Company Snapshot: ESPR  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Esperion to Present at Rodman & Renshaw Techvest Healthcare Conference

    ANN ARBOR, Mich., Oct. 17 /PRNewswire-FirstCall/ -- Esperion Therapeutics,
Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to the discovery,
development and commercialization of therapies to improve the treatment of
cardiovascular disease, today announced that Timothy M. Mayleben, Chief
Operating Officer and Chief Financial Officer, will present at the Rodman &
Renshaw Techvest Healthcare Conference on Tuesday, October 21, 2003 in Boston.
Mr. Mayleben is scheduled to speak at 9:40 a.m. (EDT).
    Investors and others may access a live audio webcast of the presentation
at http://www.esperion.com by first clicking the Investor Relations link and
then clicking the Calendar link.  A webcast replay of the Esperion
presentation may be accessed until November 4, 2003 by first clicking the
Investor Relations link and then clicking the Audio/Visual Archives link.

    Esperion Therapeutics
    Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease.  Esperion intends to
commercialize a novel class of drugs that focuses on a new treatment approach
called "HDL Therapy," which is based on the Company's understanding of high-
density lipoprotein, or HDL, function.  HDL is the primary facilitator of the
reverse lipid transport, or RLT, pathway by which excess cholesterol and other
lipids are removed from artery walls and other tissues and are transported to
the liver for elimination from the body.  Esperion's goal is to develop drugs
that exploit the beneficial functions of HDL within the RLT pathway.  Esperion
currently has four product candidates in clinical development.  Esperion is
listed on the Nasdaq National Market under the symbol "ESPR."

    Company   Amy Cannon
    Contact:  Manager, Corporate Communications
              Esperion Therapeutics, Inc.
              (734) 222-1801
              acannon@esperion.com


SOURCE Esperion Therapeutics, Inc.




Back to Topback to top

Related links:
  • http://www.esperion.com
    CONTACT:
    Amy Cannon, Manager, Corporate Communications
    of Esperion Therapeutics, Inc., +1-734-222-1801, or
    acannon@esperion.com